A Radiologist's Perspective on Treatment-Related Pseudoprogression: Clues and Hues

Chakrabarty, Nivedita; Mahajan, Abhishek; Baheti, Akshay D.; Choudhari, Amit; Patil, Vasundhara; Popat, Palak; Unde, Himangi

doi:10.1055/s-0042-1742609

Cited by 5 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging response assessment of extracerebral metastatic disease for those on systemic therapy should be performed using the latest version of Response Evaluation Criteria in Solid Tumors (RECIST 1.1) after chemotherapy and immune RECIST (iRECIST) after immunotherapy [100][101][102][103][104]. For the evaluation of the response of brain metastasis after chemotherapy, response assessment in neuro-oncology brain metastases (RANO BM) is used [101,105].…”

Section: Follow-upmentioning

confidence: 99%

Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma

Chakrabarty,

Mahajan,

Basu

et al. 2024

JCM

Self Cite

View full text Add to dashboard Cite

Thyroid cancer is the most common head and neck cancer (HNC) in the world. In this article, we comprehensively cover baseline, posttreatment, and follow-up imaging recommendations for thyroid carcinomas along with the eighth edition of the tumor, node, metastasis (TNM) staging system proposed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). We include characterization and risk stratification of thyroid nodules on ultrasound (US) proposed by various international bodies. Management guidelines (depending upon the type of thyroid carcinoma) based on the international consensus recommendations (mainly by the American Thyroid Association) are also extensively covered in this article, including the role of a radioiodine scan. The management of recurrent disease is also briefly elucidated in this article. In addition, we cover the risk factors and etiopathogenesis of thyroid carcinoma along with the non-imaging diagnostic workup essential for thyroid carcinoma management, including the significance of genetic mutations. US is the diagnostic imaging modality of choice, with US-guided fine needle aspiration (FNA) being the procedure of choice for tissue diagnosis. The roles of computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) in thyroid carcinoma staging are also specified. Through this article, we aim to provide a comprehensive reference guide for the radiologists and the clinicians in the pursuit of optimal care for patients with thyroid carcinoma.

show abstract

Section: Follow-upmentioning

confidence: 99%

Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma

Chakrabarty,

Mahajan,

Basu

et al. 2024

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…38 Im-mune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) is used for assessing response in advanced EC receiving immunotherapy to take into account the phenomenon of pseudoprogression. 39,40 ►Fig. 5 (A and B) shows pre-treatment and postradiotherapy response on PET/CT.…”

Section: D) Response Assessmentmentioning

confidence: 99%

Imaging Recommendations for Diagnosis, Staging, and Management of Esophageal Cancer

Chakrabarty

Mahajan

Prabhash

et al. 2023

Indian J Med Paediatr Oncol

Self Cite

View full text Add to dashboard Cite

Early staging and treatment initiation affect prognosis of patients with esophageal and esophagogastric junction cancer; hence, it is imperative to have knowledge of proper choice of imaging modality for staging of these patients, to effectively convey relevant imaging findings to the treating physician/surgeon. It is also essential to be aware of pertinent imaging findings that need to be conveyed to the treating physician/surgeon at staging, and after treatment, including post-therapy complications (if any), so as to provide timely management to such patients. In this article, we have provided imaging guidelines for diagnosis, staging, post-therapy response evaluation, follow-up, and assessment of post-therapy complications of esophageal and esophagogastric junction cancer in a systematic manner. Besides, risk factors and clinical workup have also been elucidated. We have also attached comprehensive staging and post-therapy contrast-enhanced computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography-based synoptic reporting formats “ECI-RADS” and “pECI-RADS,” respectively, for esophageal and esophagogastric junction cancer in the supplement, for effective communication of imaging findings between a radiologist and the treating physician/surgeon.

show abstract

Imaging of brain metastasis in non-small-cell lung cancer: indications, protocols, diagnosis, post-therapy imaging, and implications regarding management

Chakrabarty¹,

Mahajan²,

Patil³

et al. 2023

Clinical Radiology

View full text Add to dashboard Cite

A Radiologist's Perspective on Treatment-Related Pseudoprogression: Clues and Hues

Cited by 5 publications

References 28 publications

Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma

Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma

Imaging Recommendations for Diagnosis, Staging, and Management of Esophageal Cancer

Imaging of brain metastasis in non-small-cell lung cancer: indications, protocols, diagnosis, post-therapy imaging, and implications regarding management

Contact Info

Product

Resources

About